---
title: "CTOR.US (CTOR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CTOR.US/news.md"
symbol: "CTOR.US"
name: "CTOR.US"
parent: "https://longbridge.com/en/quote/CTOR.US.md"
datetime: "2026-05-21T15:18:47.869Z"
locales:
  - [en](https://longbridge.com/en/quote/CTOR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CTOR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CTOR.US/news.md)
---

# CTOR.US (CTOR.US) — Related News

### [Citius Oncology | 8-K: FY2026 Q2 Revenue: USD 1.667 M](https://longbridge.com/en/news/286613671.md)
*2026-05-15T20:47:10.000Z*
### [16:30 ETCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update](https://longbridge.com/en/news/286611505.md)
*2026-05-15T20:34:07.000Z*
> Citius Pharmaceuticals, Inc. reported $5.6 million in net revenue for the first half of fiscal 2026, driven by the launc

### [Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | CTOR Stock News](https://longbridge.com/en/news/286611095.md)
*2026-05-15T12:30:42.000Z*
> Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | CTOR Stock New

### [Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility](https://longbridge.com/en/news/285780539.md)
*2026-05-08T22:05:15.000Z*
> Citius Pharmaceuticals has amended a $3.8 million promissory note to enhance flexibility. The repayment is now deferred 

### [Citius raises $36.5m for Lymphir commercialisation](https://longbridge.com/en/news/285400494.md)
*2026-05-06T12:04:52.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization | CTOR Stock News](https://longbridge.com/en/news/285283589.md)
*2026-05-05T16:00:49.000Z*
> Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization |